A Double-blind Comparison of Clomipramine, Desipramine, and Placebo in the Treatment of Autistic Disorder

Archives of General Psychiatry

Volumn 50, Issue 6, 1993, Pages 441-447

  Gordon, Charles T ^a   State, Rosanne C ^a   Nelson, Jean E ^a   Hamburger, Susan D ^a   Rapoport, Judith L ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIPRAMINE; DESIPRAMINE; PLACEBO;

ADOLESCENT; ADULT; AGGRESSION; ANGER; ARTICLE; AUTISM; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; COMMUNICATION DISORDER; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; FLUSHING; GRAND MAL SEIZURE; HUMAN; HYPERACTIVITY; IMAGINATION; IRRITABILITY; MALE; OBSESSION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SEDATION; STEREOTYPY; TACHYCARDIA; TREMOR; XEROSTOMIA;

ADOLESCENT; ADULT; AMBULATORY CARE; AUTISTIC DISORDER; CHILD; CLOMIPRAMINE; COMPARATIVE STUDY; DESIPRAMINE; DOUBLE-BLIND METHOD; FEMALE; HUMAN; MALE; OBSESSIVE-COMPULSIVE DISORDER; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; STEREOTYPED BEHAVIOR; TREATMENT OUTCOME;

EID: 0027158571     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1993.01820180039004     Document Type: Article

References (42)

1. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987: 33–39.
2. Ritvo ER, Freeman BJ, Pingree C, Mason-Brothers A, Jorde L, Jenson WR, McMahon WM, Petersen PB, Mo A, Ritvo A. The UCLA-University of Utah Epidemiologic Survey of Autism: prevalence. Am J Psychiatry. 1989;146: 194–199.
3. Wing L. Diagnosis and Treatment of Autism. New York, NY: Plenum Press; 1989.
4. Kanner L. Autistic disturbances of affective contact. Nerv Child. 1943;8: 477–479.
5. Flament MF, Rapoport JL, Berg CJ, Kilts C. A controlled trial of clomipramine in childhood obsessive-compulsive disorder. Psychopharmacol Bull. 1985;21: 150–152.
6. Leonard HL, Swedo SE, Rapoport JL, Koby EV, Lenane MC, Cheslow DL, Hamburger SD. Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. Arch Gen Psychiatry. 1989;46: 1088–1092.
7. Swedo S, Leonard H, Rapoport J, Lenane MC, Goldberger EL, Cheslow DL. A double-blind comparison of clomipramine and desipramine in the treatment of trichotillomania (hair pulling). N Engl J Med. 1989;321: 497–501.
8. Leonard H, Lenane M, Swedo S, Rettew DC, Rapoport JL. A double-blind comparison of clomipramine and desipramine in the treatment of onychophagia. Arch Gen Psychiatry. 1991;48: 821–827.
9. Gordon CT, Rapoport JL, Hamburger SD, State RC, Mannheim GB. Differential response of seven subjects with autistic disorder to clomipramine and desipramine. Am J Psychiatry. 1992;149: 363–366.
10. Le Couteur A, Rutter M, Lord C, Rios P, Robertson S, Holdgrafer M, McLennan J. Autism Diagnostic Interview: a standardized investigator-based instrument. J Autism Dev Disord. 1989;19: 363–387.
11. Fish B. Children's Psychiatric Rating Scale. Psychopharmacol Bull. 1985;21: 753–770.
12. National Institute of Mental Health. Clinical Global Impressions. Psychopharmacol Bull. 1985;21: 839–843.
13. Murphy DL, Pickar D, Alterman IS. Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EL, Sudilovsky A, Gershon S, eds. The Behavior of Psychiatric Patients. New York, NY: Marcel Dekker Inc; 1982: 355–392.
14. Baxter LR, Phelps ME, Mazziotta JC, Giuze BH, Schwartz JM, Selin CE. Local cerebral glucose metabolic rates in obsessive compulsive disorder: a comparison with rates in unipolar depression and in normal controls. Arch Gen Psychiatry. 1987;44: 211–218.
15. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall G. A comprehensive psychopathological rating scale. Acta Psychiatr Scand. 1978;271: 5–27.
16. Campbell M, Palij M. Measurement of side effects including tardive dyskinesia. Psychopharmacol Bull. 1985;21: 1063–1082.
17. Overall JE, Campbell M. Behavioral assessment of psychopathology in children: infantile autism. J Clin Psychol. 1988;44: 708–716.
18. Winchel RM, Stanley M. Self injurious behavior: a review of the behavior and biology of self mutilation. Am J Psychiatry. 1991;148: 306–317.
19. Lipinski JF. Clomipramine in treatment of self-mutilating behaviors. N Engl J Med. 1991;324:1441.
20. Garber HJ, McGonigle JJ, Monteverde E. Clomipramine treatment of stereotypic behaviors and self-injury in patients with developmental disabilities. J Am Acad Child Adolesc Psychiatry. 1992;31: 1157–1160.
21. Todd RD. Fluoxetine in autism. Am J Psychiatry. 1991;148:1089.
22. McDougle CJ, Price LH, Goodman WK. Fluvoxamine treatment of coincident autistic disorder and obsessive compulsive disorder: a case report. J Autism Dev Disord. 1990;20: 537–543.
23. Mehlinger R, Scheftner WA, Poznanski E. Fluoxetine and autism. J Am Acad Child Adolesc Psychiatry. 1990;29:985.
24. McDougle CJ, Price LH, Volkmar FR, Goodman WK, Ward-O'Brien D, Nielsen J, Bregman J, Cohen DJ. Clomipramine in autism: preliminary evidence of efficacy. J Am Acad Child Adolesc Psychiatry. 1992;31: 746–750.
25. Cook EH, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31: 739–745.
26. Anderson LT, Campbell M. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;2: 227–239.
27. Ornitz E. Should autistic children be treated with haloperidol? Am J Psychiatry. 1985;142: 883–884.
28. Campbell M, Adams P, Perry R, Spencer EK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull. 1988;24: 251–255.
29. Campbell M, Fish B, Shapiro T, Floyd A. Imipramine in preschool autistic and schizophrenic children. J Autism Child Schizophr. 1971;1: 267–282.
30. Cook EH. Autism: review of neurochemical investigation. Synapse. 1990;6: 292–230.
31. McBride PA, Anderson GM, Hertzig ME, Sweeney JA, Kream J, Cohen DJ, Mann JJ. Serotonergic responsivity in male young adults with autistic disorder. Arch Gen Psychiatry. 1989;46: 213–221.
32. Insel TR. Serotonin in obsessive-compulsive disorder. Psychiatr Ann. 1990;20: 560–564.
33. Cleinschmidt BV, McGuffin JC. Pharmacological differentiation of the central 5-hydroxytryptamine-like actions of MK-212, p-methocyamphetamine and fenfluramine in an in vivo model system. Eur J Pharmacol. 1978;50:369.
34. Fuxe K, Farnebo LO, Hamberger B, Ogren SO. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, and their relation to the anorectic activity of fenfluramine. Postgrad Med J. 1975;51(suppl 1): 35–45.
35. Garattini S, Buczko W, Jori A, Samanin R. The mechanism of action of fenfluramine. Postgrad Med J. 1975;51(suppl 1):27.
36. Kannengiesser MH, Hunt PF, Raynaud JP. Comparative action of fenfluramine on the uptake and release of serotonin and dopamine. Eur J Pharmacol. 1976;35:35.
37. Aman MG, Kern RA. Review of fenfluramine in the treatment of the developmental disabilities. J Am Acad Child Adolesc Psychiatry. 1989;28: 549–565.
38. Balsara JJ, Jadhav JH, Chandorkar, AG. Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology. 1979;62: 67–69.
39. Gately PF, Poon SL, Segal DS, Geyer MA. Depletion of brain serotonin by 5,7dihydroxytryptamine alters the response to amphetamine and the habituation of locomotor activity in rats. Psychopharmacology. 1985;87: 400–405.
40. Korsgaard S, Gerlach J, Christensson E. Behavioral aspects of serotonindopamine interaction in the monkey. Eur J Pharmacol. 1985;118: 245–252.
41. Hall H, Ogren S. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol. 1981;70: 393–407.
42. Baxter LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin C, Ferng H, Munford P, Phelps ME. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch Gen Psychiatry. 1992;49: 681–689.